Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
British Journal of Cancer2016Vol. 115(7), pp. 789–796
Citations Over TimeTop 10% of 2016 papers
Angus Dalgleish, Justin Stebbing, Douglas JA Adamson, Seema Safia Arif, Paolo Bidoli, David K. Chang, Sue Cheeseman, Robert Díaz Beveridge, Carlos Fernández-Martos, Rob Glynne‐Jones, Cristina Granetto, Bartomeu Massutí, Karen McAdam, Ray McDermott, Andrés J. Muñoz Martín, Demetris Papamichael, Roberto Pazo-Cid, José María Viéitez, Alberto Zaniboni, Kevin J. Carroll, Shama Wagle, Andrew Gaya, Satvinder Mudan
Abstract
IMM-101 with GEM was as safe and well tolerated as GEM alone, and there was a suggestion of a beneficial effect on survival in patients with metastatic disease. This warrants further evaluation in an adequately powered confirmatory study.
Related Papers
- → USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy(2018)69 cited
- → Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells(2014)54 cited
- → Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer(2014)31 cited
- → Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine(2022)10 cited
- → Aberrant expression of circulating microRNAs in pancreatic cancer patients and in patients with gemcitabine resistance(2014)